Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells $330,093.99 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian sold 7,131 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the transaction, the chief executive officer now directly owns 70,720 shares in the company, valued at approximately $3,273,628.80. The trade was a 9.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tarsus Pharmaceuticals Trading Up 0.1 %

Tarsus Pharmaceuticals stock opened at $49.97 on Friday. The business has a 50-day simple moving average of $48.48 and a two-hundred day simple moving average of $45.35. The company has a market cap of $1.92 billion, a P/E ratio of -13.12 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. The business had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $25,000. GF Fund Management CO. LTD. purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $44,000. R Squared Ltd purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $53,000. Quarry LP purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $166,000. Finally, HighTower Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $207,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TARS has been the topic of a number of research analyst reports. Barclays lowered their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Jefferies Financial Group upped their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, March 6th. HC Wainwright reaffirmed a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating and set a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Finally, Oppenheimer upped their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.